INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on December 28, 2023. The report details a material definitive agreement entered into on the same date regarding the amendment of a Common Stock Purchase Warrant with an institutional investor.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a warrant amendment.
Material Changes and Agreement Details
- Warrant Amendment: The Company amended a Common Stock Purchase Warrant originally issued on March 27, 2023.
- Share Count: The warrant covers 276,000 shares of Common Stock (adjusted from 5,520,000 shares following a 1-for-20 reverse stock split in July 2023).
- Exercise Price Adjustment: The exercise price was reduced from $12.60 per share to $2.85 per share.
- Context: This reduction aligns the warrant price with the $2.85 per unit price of the Company's Public Offering that closed on August 8, 2023.
- Shareholder Approval: The reduction was approved by shareholders at the 2023 Annual Meeting of Stockholders on December 26, 2023, in accordance with Nasdaq Listing Rule 5635(d).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure that the summary is qualified by the full text of the Amendment attached as Exhibit 4.1.
Key Facts for Investor Verification
- Verify the full text of the Amendment to Common Stock Purchase Warrant (Exhibit 4.1) for any additional covenants or conditions not summarized here.
- Confirm the impact of the 276,000 shares potentially being issued upon exercise at the new $2.85 price point on existing shareholder dilution.
- Review the Company's recent stock price relative to the new $2.85 exercise price to assess the likelihood of immediate warrant exercise.